Hale Animal Health is leading the way in the development of novel therapeutics for companion animals. They are at the cutting edge of animal health and are currently developing one of the world’s first cannabis derived prescription medications that will be registered as a veterinary medicine at a global scale.

Founded in 2020, by Leila de Koster, Hale is initially developing an animal pharmaceutical drug that will be used to treat pain in dogs suffering from osteoarthritis. The drug will treat pain just as effectively as conventional drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) but without the nasty side-effects. When approved, the product will be the first cannabis-derived animal pharmaceutical available in market.

Hale is poised to be a first mover in this market, which will take advantage of a unique product that has a differentiated approach to solving a growing animal health issue, that is at the cusp of a major shift in the global medicinal cannabis market opportunity.

Hale has recently secured a major New Zealand venture capital fund as their lead investor. The lead investor is bringing $1.3 million to this capital raise round, leaving just $0.7 million left to raise.